The accelerating pace of drug development, and the translation of genomic information into actionable insights for disease treatment offers tremendous opportunity for innovative companies to address unmet medical needs.
Marc Schneidman (CIO, Acquilo Capital Managemen) joins us to discuss biotech’s exciting new era.